Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways (Q37616238)

21 August 2017

1 reference

title

Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways (English)

1 reference

21 August 2017

Alexander Lazar

2

0 references

author name string

Daniela Katz

series ordinal

1

1 reference

21 August 2017

Dina Lev

series ordinal

3

1 reference

21 August 2017

publication date

19 October 2009

1 reference

Expert Reviews in Molecular Medicine

21 August 2017

published in

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

page(s)

e30

1 reference

Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Expression and significance of EGFR in malignant peripheral nerve sheath tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Lipid posttranslational modifications. Farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The ins and outs of Raf kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Association between benign and malignant peripheral nerve sheath tumors in NF1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Neurogenic sarcomas: experience at the University of Toronto.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Pathophysiology of neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

A role for Pak protein kinases in Schwann cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

VEGF-A splicing: the key to anti-angiogenic therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Signal transduction from multiple Ras effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Radiation induced peripheral nerve tumors: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Markers of angiogenesis and clinical features in patients with sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Neurofibromas in NF1: Schwann cell origin and role of tumor environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

It takes a (dysfunctional) village to raise a tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Connecting signaling and cell cycle progression in growth factor-stimulated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The biology behind mTOR inhibition in sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

A 10-year review of benign and malignant peripheral nerve sheath tumors in a single center: clinical and radiographic features can help to differentiate benign from malignant lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Elevated risk for MPNST in NF1 microdeletion patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

An expanding role for mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Developmental roles of platelet-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Growth factors: Mechanism of action and relation to oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

Differential expression of angiogenic factors in peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Neurofibromin as a regulator of melanocyte development and differentiation

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

TP53 mutations are frequent in malignant NF1 tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

The value of magnetic resonance imaging in the differentiation between malignant peripheral nerve-sheath tumors and non-neurogenic malignant soft-tissue tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): a 10-year experience

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Malignant peripheral nerve sheath tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Subclassification of nerve sheath tumors by gene expression profiling

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Malignant schwannoma--clinical characteristics, survival, and response to therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Survival data for patients with malignant schwannoma.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Malignant peripheral nerve sheath tumor: analysis of treatment outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Neurofibromatosis type 1 - a model for nervous system tumour formation?

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

SARCOMAS OF THE PERIPHERAL NERVES AND SOMATIC SOFT TISSUES ASSOCIATED WITH MULTIPLE NEUROFIBROMATOSIS (VON RECKLINGHAUSEN'S DISEASE)

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases

1 reference

https://api.crossref.org/works/10.1017%2FS1462399409001227

7 January 2021

10.1017/S1462399409001227

Identifiers

DOI

1 reference

21 August 2017

1 reference